β-blockers after myocardial infarction and 1-year clinical outcome - A retrospective study

Research output: Contribution to journalArticle

Bibtex

@article{497381e3509147a08299cc0a0ec1c6b0,
title = "β-blockers after myocardial infarction and 1-year clinical outcome - A retrospective study",
abstract = "Background: Long term β-blocker therapy after myocardial infarction (MI) reduces mortality and recurrent MI but evidence for this treatment predates contemporary acute coronary care. β-blocker treatment is a key quality of care indicator in the Swedish national quality register for acute coronary care, Riks-HIA. Between 2011 and 2015 a declining number of MI-patients discharged with a β-blocker from the coronary care unit (CCU) at Helsingborg and other hospitals was reported. This retrospective observational study aimed to investigate the causes for discharge without a β-blocker and relate it to outcome, compared to patients discharged with a β-blocker. Methods: MI-patients registered in Riks-HIA discharged without β-blocker during 2011-2015 (no-β-group) and a control group (β-group) comprised of patients discharged with β-blocker treatment between January 1 to December 31, 2013, were matched by RIKS-HIA criteria for β-blocker use. Clinical characteristics, date of death, readmission for MI, other cardiovascular events were collected from Riks-HIA and medical records. Results: The no-β-group included 141 patients, where 65.2% had a justified reason for non-β-blocker use. The β-group included 206 patients. There was no difference in cardiovascular risk factor profile. There were a trend towards a higher number of readmissions for MI in the no-β-group was (n = 8 (5.7%) vs n = 2 (1.0%), p = 0.02), but not mortality (6 (4.3%) vs 2 (1.0%), p = 0.07) and combined readmission for angina pectoris, heart failure, arrhythmias or stroke/TIA (n = 23 (16.3%) vs n = 25 (12.1%), p = 0.27). Conclusion: A majority of the patients in the no-β-group had a justified absence of a β-blocker. β-blocker treatment post-MI showed a trend towards fewer readmissions for MI. But important quality information is lacking to make a firm conclusion of the effect on outcome.",
keywords = "Beta-blockers, Myocardial infarction, Riks-HIA, Secondary prevention",
author = "Tora Hagsund and Olsson, {Sven Erik} and Smith, {J. Gustav} and {Madsen Hardig}, Bjarne and Henrik Wagner",
year = "2020",
month = apr,
day = "9",
doi = "10.1186/s12872-020-01441-0",
language = "English",
volume = "20",
journal = "BMC Cardiovascular Disorders",
issn = "1471-2261",
publisher = "BioMed Central (BMC)",
number = "1",

}